Researchers from the MD Anderson Cancer Center presented data from a study that assessed the tumor microenvironment (TME) of adenoid cystic carcinoma (ACC) with the aim of identifying novel therapeutic targets for ACC.
Microtubule-targeting agents impact microtubule dynamics to induce mitotic arrest and tumor cell death. Tubulin is therefore a relevant target for the discovery of new agents acting as tumor neovasculature disruptors. Researchers from Nanjing Keygen Biotech Co. Ltd. have reported on the design and optimization of novel tubulin polymerization inhibitors with antiangiogenesis activity that led to the identification of [I] as the compound.
Enliven Therapeutics Inc. has synthesized HER2 (erbB2) inhibitors, including Exon 20 insertion (Ex20Ins) mutant inhibitors, reported to be useful for the treatment of cancer.
Researchers from Bristol Myers Squibb Co. recently discussed the discovery and preclinical characterization of a series of Toll-like receptor 7 (TLR7) agonists with potential as anticancer drug candidates.
Molecular glue degraders are compounds intended to prompt the degradation of E3 ubiquitin ligases by engaging and modifying their surface. Molecular glue-induced protein degradation is considered an emerging strategy in drug discovery.
Beactica Therapeutics AB has selected BEA-17 as a preclinical candidate from its lysine demethylase 1 (LSD1) program targeting aggressive brain tumors and other cancers, and IND-enabling toxicology studies will now be initiated.
Investigators at Cold Spring Harbor Laboratory have discovered a method of switching cancerous rhabdomyosarcoma cells back into normal muscle cells that could lead to the development of a treatment for this rare aggressive childhood cancer.
RSS
